REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1

Q4 2021 13F Holders as of 31 Dec 2021

Type / Class
Debt / NOTE 1.750% 2/1
Number of holders
19
Total 13F principal, excl. options
252,502,187
Principal change
-13,976,813
Total reported value, excl. options
$225,617,587
Value change
-$17,407,568
Number of buys
12
Number of sells
-10
Price
$0.883

Significant Holders of REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 as of Q4 2021

26 filings reported holding 761330AB5 - REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 as of Q4 2021.
REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 has 19 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of $252,502,187 of principal .
Largest 10 bondholders include CITADEL ADVISORS LLC ($78,204,000 of principal), FRANKLIN RESOURCES INC ($48,000,000 of principal), Antara Capital LP ($32,000,000 of principal), LAZARD ASSET MANAGEMENT LLC ($31,545,000 of principal), CAPSTONE INVESTMENT ADVISORS, LLC ($15,500,000 of principal), AVIVA PLC ($10,000,000 of principal), LMR Partners LLP ($6,500,000 of principal), AMUNDI ($6,232,000 of principal), COURAGE CAPITAL MANAGEMENT LLC ($5,905,000 of principal), and MORGAN STANLEY ($4,208,000 of principal).
This table shows the top 19 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
Investor Option Weight % Change % Value $ * Price $ Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.